Navigation Links
CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research
Date:5/9/2011

Building on its extensive laboratory research using magnetically guided nanoparticles to deliver drugs to diseased blood vessels, The Children's Hospital of Philadelphia has just spun off its first startup company, Vascular Magnetics, Inc. (VMI).

By licensing its technology to VMI, a new company formed to develop the lab findings into a commercially viable therapy, the Hospital aims to create a novel, greatly needed treatment for peripheral artery disease (PAD). Characterized by blocked arteries, primarily in the legs, PAD affects more than 27 million older adults in North America and Europe, with diabetes patients and smokers at particularly high risk. Current treatments for PAD, including drug-eluting stents, are ineffective, with re-blockage of the arteries occurring at a high rate.

In addition to being the Hospital's first startup company, the program targets patients outside the Hospital's usual pediatric age group. "While our first target group is adult patients, the technique represents a new platform technology, potentially adaptable to delivering a variety of therapies to children as well as adults," says the technology's inventor, Robert J. Levy, M.D., the William J. Rashkind Endowed Chair in Pediatric Cardiology at The Children's Hospital of Philadelphia.

Levy co-founded VMI with Richard S. Woodward, Ph.D., the company's Chief Executive Officer. The two first joined forces through the QED Proof-of-Concept Program sponsored by the University City Science Center in West Philadelphia. The goal of the QED Program, the nation's first multi-institutional proof-of-concept program for life sciences technologies, is to accelerate research from academic laboratories into the marketplace. A unique feature of this program is that academic scientists such as Levy are partnered with experienced business advisors such as Woodward, who has a background that includes developing nanoparticles and polymeric coatings.

"The Science Cen
'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. D.C.-area science teachers experimenting with partnerships
2. University of Illinois partners in $9.6 million grant to bolster food security in India
3. Researchers develop curious snapshot of powerful retinal pigment and its partners
4. Optiqua-NTU partnership to develop next-generation sensor technology
5. Partnership of genes affects the brains development
6. Tufts announces public launch of the Tufts Institute for Biomedical Partnerships website/HUB
7. memsys-NTU partnership to enhance water desalination technology
8. SU biologist partners with National Park Service to study bison grazing in Yellowstone
9. Partnership Is Game-Changer for the Future of eCommerce
10. Agilent Technologies Expands Agreement to Offer AMDeC Members Preferential Pricing on Products Through AMDeC F.I.R.S.T.™ Vendor Partnership Program
11. National Zoo and partners first to breed critically endangered tree frog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
(Date:5/20/2013)... Minnesota Medical School researchers from the Masonic Cancer Center, ... Tumor Program, have developed a new mouse model of ... to discover new genes and gene pathways driving this ... week in the journal Nature Genetics . , ... lab of David Largaespada, Ph.D., professor in the Medical ...
(Date:5/20/2013)... DIEGO (May 20, 2013) - A novel ... headline the groundbreaking research that will be unveiled at ... Conference (NBC). The meeting takes place Monday, May 20 ... Hotel and Marina. , "The main goal of ... fight against a pathogen that causes the disease", explained ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... parts of the shark and are often removed from the body, ... practice, many countries allow the fins to be landed detached from ... per cent of the total shark catch. New University of British ... A study published this week in the journal ...
... to their doctor for a blood test generally has to ... of uncertainty can make patients anxious especially in critical ... it takes so long for laboratories to analyze samples is ... Each sample must be accompanied by meticulous records, so lab ...
... Md. (March 1, 2012)The American Physiology Society (APS) has announced ... experimental animals and the sex or gender of humans used ... 13 peer-reviewed journals. This notable requirement for all research study ... be presented in an editorial, " In Pursuit of Scientific ...
Cached Biology News:Law that regulates shark fishery is too liberal: UBC study 2'Labor der Zukunft' -- Tomorrow's laboratory technology 2'Labor der Zukunft' -- Tomorrow's laboratory technology 3APS issues new policy requiring identification of sex or gender in reporting scientific research 2APS issues new policy requiring identification of sex or gender in reporting scientific research 3
(Date:5/21/2013)... The Formulate Fusion Fabric Display ... and marketing teams looking for a fully-functional package for their ... “everything you’ll need to put together a stunning and eye-catching ... a number of displays and accessories that can be quickly ... 20 feet in size. These components vary from kit to ...
(Date:5/20/2013)... -- , Collaboration with the U.S. ... in treatment of mastitis , Major ... begin in the second half 2013 ... Limited (ASX: POH, OTCQX: PPGNY) will collaborate with ... (ARS) to develop and trial products targeting the serious ...
(Date:5/20/2013)... Pa (PRWEB) May 20, 2013 Oven ... with ramp/soak capabilities. The 5R6-900 benchtop controller has ... the device can be plugged into the wall as ... power supply. This distinctive detail makes the device unique, ... , The laboratory temperature controller can also be used ...
(Date:5/20/2013)... -- Today, at the American Psychiatric Association (APA) Meeting ... James McGough , M.D., M.S., principal investigator and ... Neuroscience and Human Behavior and David Geffen ... California Los Angeles (UCLA), and director of clinical teaching ... at UCLA, presented the results of a Phase I ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5
... People Living with ... Fibromyalgia -, INDIANAPOLIS, Oct. ... Martha Beck, one day became a seemingly,endless cycle of widespread pain, fatigue, ... answer to the painful,symptoms she was experiencing before she finally received a ...
... Data on Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in,Development ... and,Community Acquired Pneumonia (CAP), WASHINGTON, Oct. 27, ... presented a detailed analysis of CANVAS I, a,globally ... 48th,Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ...
... Today to ... Discuss Results, BIRMINGHAM, ... announced results of an,exploratory Phase 2 trial of intravenous (i.v.) peramivir, ... The Phase 2 trial compared the efficacy and,safety of five days ...
Cached Biology Technology:From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 2From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 3From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 4From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 3Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 4Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 6Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 7Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 8BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: